195 related articles for article (PubMed ID: 36246666)
1. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy.
Liu S; Wu J; Feng Y; Guo X; Li T; Meng M; Chen J; Chen D; Tian H
Bioact Mater; 2023 Apr; 22():211-224. PubMed ID: 36246666
[TBL] [Abstract][Full Text] [Related]
2. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
3. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
4. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
5. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
6. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody.
Li Z; Cai H; Li Z; Ren L; Ma X; Zhu H; Gong Q; Zhang H; Gu Z; Luo K
Bioact Mater; 2023 Mar; 21():299-312. PubMed ID: 36157245
[TBL] [Abstract][Full Text] [Related]
7. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
8. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
9. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger.
Hu Y; Lin L; Chen J; Maruyama A; Tian H; Chen X
Biomaterials; 2020 Sep; 252():120114. PubMed ID: 32422491
[TBL] [Abstract][Full Text] [Related]
10. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Chen J; Fang H; Hu Y; Wu J; Zhang S; Feng Y; Lin L; Tian H; Chen X
Bioact Mater; 2022 Jan; 7():167-180. PubMed ID: 34466725
[TBL] [Abstract][Full Text] [Related]
11. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
12. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
13. Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy.
Zhan J; Zhang M; Zhou L; He C
Front Bioeng Biotechnol; 2023; 11():1065773. PubMed ID: 36994358
[TBL] [Abstract][Full Text] [Related]
14. Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy.
Xiong X; Zhao J; Pan J; Liu C; Guo X; Zhou S
Nano Lett; 2021 Oct; 21(19):8418-8425. PubMed ID: 34546061
[TBL] [Abstract][Full Text] [Related]
15. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality.
Kang T; Huang Y; Zhu Q; Cheng H; Pei Y; Feng J; Xu M; Jiang G; Song Q; Jiang T; Chen H; Gao X; Chen J
Biomaterials; 2018 May; 164():80-97. PubMed ID: 29499438
[TBL] [Abstract][Full Text] [Related]
16. Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
Kim Y; Kang S; Shin H; Kim T; Yu B; Kim J; Yoo D; Jon S
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14628-14638. PubMed ID: 32430981
[TBL] [Abstract][Full Text] [Related]
17. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
Wang X; Li X; Ito A; Sogo Y; Ohno T
Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
[TBL] [Abstract][Full Text] [Related]
19. In Situ Cocktail Nanovaccine for Cancer Immunotherapy.
Liu M; Xie D; Hu D; Zhang R; Wang Y; Tang L; Zhou B; Zhao B; Yang L
Adv Sci (Weinh); 2023 Nov; 10(31):e2207697. PubMed ID: 37740439
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
[Next] [New Search]